Distinction between benign and malignant type of parkinson's disease
Identifieur interne : 002B81 ( Main/Exploration ); précédent : 002B80; suivant : 002B82Distinction between benign and malignant type of parkinson's disease
Auteurs : W. Birkmayer [Autriche] ; P. Riederer [Autriche] ; M. B. H. Youdim [Israël]Source :
- Clinical Neurology and Neurosurgery [ 0303-8467 ] ; 1979.
Abstract
Clinical data demonstrate that there is a significant difference between at least two types of idiopathic Parkinsonian patients; a benign type of Parkinson's disease and a malignant type.They can be distinguished by the time course of a disability-score, independent of the duration of the disease.The benign cases respond very well to L-Dopa (Madopar) treatment and show a long lasting (7 years) drop in the disability, whereas the improvement of disability in the malignant cases is much smaller and lasts for about one year, followed by an increase of disability.The duration of the disease is 12,5 ± 0,4 years in the benign type but only 4,0 ± 0,3 years in the malignant type.Akinetic crises, off-phases, hyperkinetic crises and toxic deliria after Madopar treatment can be observed later in the benign than in the malignant cases.These results suggest that the degeneration of the dopaminergic nigrostriatal system occurs much more rapidly in malignant cases than in benign cases of Parkinson's disease.
Url:
DOI: 10.1016/0303-8467(79)90003-9
Affiliations:
Links toward previous steps (curation, corpus...)
Le document en format XML
<record><TEI wicri:istexFullTextTei="biblStruct"><teiHeader><fileDesc><titleStmt><title>Distinction between benign and malignant type of parkinson's disease</title><author><name sortKey="Birkmayer, W" sort="Birkmayer, W" uniqKey="Birkmayer W" first="W." last="Birkmayer">W. Birkmayer</name></author><author><name sortKey="Riederer, P" sort="Riederer, P" uniqKey="Riederer P" first="P." last="Riederer">P. Riederer</name></author><author><name sortKey="Youdim, M B H" sort="Youdim, M B H" uniqKey="Youdim M" first="M. B. H." last="Youdim">M. B. H. Youdim</name></author></titleStmt><publicationStmt><idno type="wicri:source">ISTEX</idno><idno type="RBID">ISTEX:9722B0CA10AE6A04185D3DAD5ED96ECDF55D037E</idno><date when="1979" year="1979">1979</date><idno type="doi">10.1016/0303-8467(79)90003-9</idno><idno type="url">https://api.istex.fr/document/9722B0CA10AE6A04185D3DAD5ED96ECDF55D037E/fulltext/pdf</idno><idno type="wicri:Area/Main/Corpus">002C69</idno><idno type="wicri:Area/Main/Curation">002897</idno><idno type="wicri:Area/Main/Exploration">002B81</idno></publicationStmt><sourceDesc><biblStruct><analytic><title level="a">Distinction between benign and malignant type of parkinson's disease</title><author><name sortKey="Birkmayer, W" sort="Birkmayer, W" uniqKey="Birkmayer W" first="W." last="Birkmayer">W. Birkmayer</name><affiliation wicri:level="1"><country xml:lang="fr">Autriche</country><wicri:regionArea>Ludwig Boltzmann Institute of Clinical Neurobiology, Lainz Hospital. A-1130 Vienna</wicri:regionArea><wicri:noRegion>Lainz Hospital. A-1130 Vienna</wicri:noRegion></affiliation></author><author><name sortKey="Riederer, P" sort="Riederer, P" uniqKey="Riederer P" first="P." last="Riederer">P. Riederer</name><affiliation wicri:level="1"><country xml:lang="fr">Autriche</country><wicri:regionArea>Ludwig Boltzmann Institute of Clinical Neurobiology, Lainz Hospital. A-1130 Vienna</wicri:regionArea><wicri:noRegion>Lainz Hospital. A-1130 Vienna</wicri:noRegion></affiliation></author><author><name sortKey="Youdim, M B H" sort="Youdim, M B H" uniqKey="Youdim M" first="M. B. H." last="Youdim">M. B. H. Youdim</name><affiliation wicri:level="1"><country xml:lang="fr">Israël</country><wicri:regionArea>Technion-Israel Institute of Technology, Faculty of Medicine, Department of Pharmacology Haifa</wicri:regionArea><wicri:noRegion>Department of Pharmacology Haifa</wicri:noRegion></affiliation></author></analytic><monogr></monogr><series><title level="j">Clinical Neurology and Neurosurgery</title><title level="j" type="abbrev">CLINEU</title><idno type="ISSN">0303-8467</idno><imprint><publisher>ELSEVIER</publisher><date type="published" when="1979">1979</date><biblScope unit="volume">81</biblScope><biblScope unit="issue">3</biblScope><biblScope unit="page" from="158">158</biblScope><biblScope unit="page" to="164">164</biblScope></imprint><idno type="ISSN">0303-8467</idno></series><idno type="istex">9722B0CA10AE6A04185D3DAD5ED96ECDF55D037E</idno><idno type="DOI">10.1016/0303-8467(79)90003-9</idno><idno type="PII">0303-8467(79)90003-9</idno></biblStruct></sourceDesc><seriesStmt><idno type="ISSN">0303-8467</idno></seriesStmt></fileDesc><profileDesc><textClass></textClass><langUsage><language ident="en">en</language></langUsage></profileDesc></teiHeader><front><div type="abstract" xml:lang="en">Clinical data demonstrate that there is a significant difference between at least two types of idiopathic Parkinsonian patients; a benign type of Parkinson's disease and a malignant type.They can be distinguished by the time course of a disability-score, independent of the duration of the disease.The benign cases respond very well to L-Dopa (Madopar) treatment and show a long lasting (7 years) drop in the disability, whereas the improvement of disability in the malignant cases is much smaller and lasts for about one year, followed by an increase of disability.The duration of the disease is 12,5 ± 0,4 years in the benign type but only 4,0 ± 0,3 years in the malignant type.Akinetic crises, off-phases, hyperkinetic crises and toxic deliria after Madopar treatment can be observed later in the benign than in the malignant cases.These results suggest that the degeneration of the dopaminergic nigrostriatal system occurs much more rapidly in malignant cases than in benign cases of Parkinson's disease.</div></front></TEI><affiliations><list><country><li>Autriche</li><li>Israël</li></country></list><tree><country name="Autriche"><noRegion><name sortKey="Birkmayer, W" sort="Birkmayer, W" uniqKey="Birkmayer W" first="W." last="Birkmayer">W. Birkmayer</name></noRegion><name sortKey="Riederer, P" sort="Riederer, P" uniqKey="Riederer P" first="P." last="Riederer">P. Riederer</name></country><country name="Israël"><noRegion><name sortKey="Youdim, M B H" sort="Youdim, M B H" uniqKey="Youdim M" first="M. B. H." last="Youdim">M. B. H. Youdim</name></noRegion></country></tree></affiliations></record>Pour manipuler ce document sous Unix (Dilib)
EXPLOR_STEP=$WICRI_ROOT/Wicri/Sante/explor/ParkinsonV1/Data/Main/Exploration
HfdSelect -h $EXPLOR_STEP/biblio.hfd -nk 002B81 | SxmlIndent | more
Ou
HfdSelect -h $EXPLOR_AREA/Data/Main/Exploration/biblio.hfd -nk 002B81 | SxmlIndent | more
Pour mettre un lien sur cette page dans le réseau Wicri
{{Explor lien
|wiki= Wicri/Sante
|area= ParkinsonV1
|flux= Main
|étape= Exploration
|type= RBID
|clé= ISTEX:9722B0CA10AE6A04185D3DAD5ED96ECDF55D037E
|texte= Distinction between benign and malignant type of parkinson's disease
}}
| This area was generated with Dilib version V0.6.23. |  |